Pyrazinamide forms a core part of treatment for all types of tuberculosis (TB) in Zambia. Due 23 to challenges associated with pyrazinamide testing, little information is available to indicate the 24 frequency of resistance to this drug in Zambia. To determine the frequency of pyarazinamide 25 (PZA) resistance and its correlation with mutation in pncA in Mycobacterium tuberculosis 26 isolated from patients in Lusaka, Zambia, BACTEC MGIT M960 was used for phenotypic PZA 27 susceptibility testing while sequencing was used to determine resistance-conferring mutations in 28 the pncA.
minute; 35 cycles of denaturation at 96°C for 10 seconds; annealing at 52°C for 10 seconds and 137 extension at 72°C for 30 seconds; and a final extension at 72°C for 5 minutes. DNA sequences of 138 amplified fragments were analysed using a BigDye ® terminator version 3.1 cycle sequence 139 reaction kit and an ABI 3130 genetic analyser (Applied Biosystems, Foster, CA, USA) in 140 accordance with the manufacturer's instructions. The obtained sequences were compared to the 141 standard sequence from M. tuberculosis H37Rv using Bioedit software. For samples that showed 142 resistance in PZA susceptibility testing, rpsA and panD sequences were also sequenced 143 according to methods described in previous studies [11] [14] [17] . tuberculosis was used for this study. Demographic data of the isolates could not be analyzed as 161 the information was incomplete in the laboratory information system. A total of 32 (24.4%) 162 isolates were found resistant to PZA. Drug susceptibility testing for these isolates was repeated 163 to confirm the resistance. Of the 32 PZA resistant isolates, resistance was reproduced in 21 164 isolates, while 2 isolates were susceptible on repeat test. Results for 9 isolates could not be 165 obtained and these were excluded bringing the total number of isolates analyzed to 122. The 166 results obtained after repeat testing were considered as true phenotype.
167
The drug susceptibility profiles of isolates showed that 32 (26.2%) were MDR-TB, while 90 168 (73.1%) were non-MDR TB as shown in table 1. Among MDR-isolates, 16 (50%) isolates were 169 phenotypically resistant to PZA as compared to 5 (5.6%) among the non-MDR-TB (P 170 value<0.0001). Pyrazinamide mono resistance was seen in eight isolates in first PZA testing but 171 on repeat, four isolates had PZA mono resistance phenotype. When PZA resistant isolates were 172 stratified into new and recurrent cases, it was observed that 1(5.6%) isolate was a new case while 173 17 (94.4%) isolates were from recurrent cases (Table 2 ). Treatment history of 3 isolates could 174 not be ascertained because of incomplete information in the laboratory information system. (Table 3) .
180
Eighteen types of mutations were exclusively identified in the 19 PZA resistant isolates. Two 181 isolates had mutations in the promoter region and both of them exhibited PZA resistant phenotype. Insertions and deletions were observed in 5 isolates. Six mutations not previously 183 described were identified in this study. Three types of mutations were observed in both 184 susceptible and resistant isolates. Two of these mutations, a synonymous C195T (S65S) and non-185 synonymous T104G (L35R) mutations were the most frequently observed mutations being 186 identified in 17 and 7 isolates, respectively. The other mutation observed in both resistant and 187 susceptible isolates was A128C (H43P).
188
To check contributions of mutations in the other genes to PZA resistance, rpsA and panD 189 sequences of the initial 32 PZA-resistant isolates were also read. It was confirmed that neither 190 rpsA nor panD in those isolates had a mutation.
191
To check mutations and lineage specificity, spoligotyping results were obtained all isolates with 192 mutations. Table 3 shows profile of pncA gene mutations from the initial PZA testing. 
